CJC-1295 DAC

Also known as: Modified GRF 1-29 DAC

Growth HormonePHASE 2

Clinical Status

Investigational — Research compound.

Mechanism of Action

Contains a reactive linker that binds to albumin after injection, extending half-life to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation.

Dosing Defaults

Dose

2 mg

Frequency

1-2x weekly

Administration

Subcutaneous injection

Timing

Before bed or morning (fasted)

Food

fasted

Duration

8-12 weeks

Dose range: 1-2 mg weekly

Long 8-day half-life makes timing less critical.

Side Effects

•Injection site reactions
•Facial flushing
•Water retention
•Headache
•Side effects persist longer due to 8-day half-life

Contraindications & Warnings

⚠Active malignancy

•Not medical advice
•Clinical trial discontinued

Compare

Compare CJC-1295 DAC with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your CJC-1295 DAC dose.

Open Calculator

Related Growth Hormone Peptides

Ipamorelin

PHASE 2

Growth Hormone

Selective GH secretagogue. Considered one of the safest GHRPs.

CJC-1295

PHASE 2

Growth Hormone

Synthetic GHRH analog that stimulates GH release from the pituitary.

Tesamorelin

FDA APPROVED

Growth Hormone

FDA-approved GHRH analog for visceral fat reduction in HIV lipodystrophy.

Sermorelin

FDA APPROVED

Growth Hormone

Truncated GHRH analog. Previously FDA-approved for pediatric GH deficiency.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.